Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONT01 and Gemcitabine/Nab-paclitaxel in Second Line Metastatic Pancreatic Cancer
NCT06904378Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ontegimod in pancreatic ductal adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Started Mar 2026; status: recruiting.
02
Drugs
ontegimod
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06904378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904378.